Results 81 to 90 of about 43,533 (201)

Classification of Human Retinal Microaneurysms Using Adaptive Optics Scanning Light Ophthalmoscope Fluorescein Angiography [PDF]

, 2014
Purpose. Microaneurysms (MAs) are considered a hallmark of retinal vascular disease, yet what little is known about them is mostly based upon histology, not clinical observation.
Carroll, Joseph, Chui, Toco Y.P., Cooper, Robert F., Dubow, Michael, Dubra, Alfredo, Gan, Alexander, Gentile, Ronald C., Hendrix, Vernon, Pinhas, Alexander, Rosen, Richard B., Shah, Nishit, Sulai, Yusufu N., Walsh, Joseph B., Weitz, Rishard   +13 more
core   +2 more sources

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

Functional deficits precede structural lesions in mice with high-fat diet-induced diabetic retinopathy [PDF]

, 2016
Obesity predisposes to human type 2 diabetes, the most common cause of diabetic retinopathy. To determine if high-fat diet–induced diabetes in mice can model retinal disease, we weaned mice to chow or a high-fat diet and tested the hypothesis that diet ...
Bligard, Gregory W, Lukasiewicz, Peter, Rajagopal, Rithwick, Semenkovich, Clay F, Yin, Li, Zhang, Sheng   +5 more
core   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography [PDF]

, 2013
Purpose: To correlate inflammatory and proangiogenic key cytokines from undiluted vitreous of treatment-naïve central retinal vein occlusion (CRVO) patients with SD-OCT parameters. Methods: Thirty-five patients (age 71.1 years, 24 phakic, 30 nonischemic)
Cinatl, Jindrich, Koch, Frank H., Kohnen, Thomas, Koss, Michael Janusz, Pfister, Marcel, Rejdak, Robert, Ribeiro, Ramiro M., Rothweiler, Florian, Schubert, Ralf   +8 more
core   +1 more source

Incidence, Progression and Determinants of Diabetic Retinopathy in Type 2 Diabetes in Australasia: A Systematic Review and Meta‐Analysis

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Current evidence on incidence and progression rate of diabetic retinopathy reveals disparities across Australasia, and no pooled estimates are available to guide region‐wide planning. This review and meta‐analysis assesses the overall incidence, determinants and progression of diabetic retinopathy in Australasia.
Getasew Alemu Mersha, Mesert Derbew Molla, Ranjay Chakraborty, Georgia Kaidonis, Stewart Lake, Jamie Craig, José Estevez   +6 more
wiley   +1 more source

Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Objective To comprehensively assess the cost‐utility of icodec, the first once‐weekly basal insulin, at 700 and 1050 U formulations compared with once‐daily basal insulin analogues in Chinese adults with type 2 diabetes within reimbursement context.
Xichen Tong, Chang Xing, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

Diabetic macular edema: it is more than just VEGF [version 1; referees: 2 approved]

F1000Research, 2016
Diabetic macular edema is a serious visual complication of diabetic retinopathy. This article reviews the history of previous and current therapies, including laser therapy, anti-vascular endothelial growth factor agents, and corticosteroids, that have ...
Michael A. Singer, Daniel S. Kermany, Jana Waters, Michael E. Jansen, Lyndon Tyler   +4 more
doaj   +1 more source

Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema

Journal of Ophthalmic & Vision Research, 2020
Purpose: To report the efficacy of topical interferon alpha 2b in the treatment of refractory diabetic macular edema. Methods: In this retrospective interventional case series, five eyes of three individuals with diabetic macular edema resistant to
Arash Maleki, Andrew Phillips Stephenson, Fedra Hajizadeh   +2 more
doaj   +1 more source

Cost‐effectiveness analysis of Dexcom ONE+ real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Real‐time continuous glucose monitors (rt‐CGM) have been found effective and economical for the treatment of diabetes in many countries. The objective of this study was to provide a cost‐effectiveness analysis of rt‐CGM versus self‐monitoring of blood glucose (SMBG) from the perspective of a healthcare payer in New Zealand.
Ryan G. Paul, Jessica Y. Matuoka, Hamza A. Alshannaq, Richard F. Pollock, Gregory J. Norman   +4 more
wiley   +1 more source